Fig. 3

Immune inhibitory molecules in MSI and MSS tumours. a quantification of infiltrating LY6G6D positive cells expressed as mean of five replicates counts, cells mm^− 2) in normal mucosa and CRC samples. Correlation between LY6G6D+ cells, p-STAT5 staining in CRC samples (five replicates counts, cells mm^− 2). b Examples of MSI and MSS CRC stained by immunohistochemistry against MLH1, LY6G6D, PDL1 and PD1. T, Tumour, S, stromal compartment. Scale bar, 50 μm. c Quantification of stromal infiltration and staining of malignant cells by immunohistochemistry for LY6G6D, PDL1 and PD1. P* < 0.05, P** < 0.01, ***P < 0.001, by the Chi-squared test. d Kaplan–Meier curve showing the time to disease progression in relation to LY6G6D and CD15 status (n = 187); The p-value by log-rank test. Response to treatment according to LY6G6D IHC in primary metastatic tumors (n = 83) subdivided for complete (CR); partial (PR) responses; stable disease (SD) and progression disease (PD); P* < 0.05, P** < 0.01, ***P < 0.001, by the Chi-squared test